Furthermore, a multicenter, non-randomized, two-arm phase I/II clinical trial evaluated the safety and immunogenicity of a DNA vaccine encoding the DOM-CAP-1 fusion gene that targets HLA-A*02:01 binding peptide CAP-1 from CEA (CEA605–613) in patients with CEA-expressing CRC (56). Here, CEACAM5 is linked to colorectal carcinoma.